Sign in and upgrade to a paid plan to export futures history as CSV.

Windlas Biotech Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: WINDLAS BSE: 543329
₹1091.30
▼ -4.95 (-0.45%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
74/100
Strong
Valuation
15/100
Expensive
Momentum
52/100
Neutral

QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹2,252 Cr
PE (TTM)
34.5
Industry median 36.1 (152 companies)
Price to Book
3.9
PEG (TTM)
16.4
Institutions holding %
11.88%
FII + DII, latest filed period
Piotroski Score
3
Relative return vs Nifty50, qtr %
31.0
Relative return vs Sector, qtr %
26.7
Free Cash Flow
₹37 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
0.36%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
2.45%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
18.53%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-0.07%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
18.09%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.95
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.05
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
16.99
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
7.12%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
9.91%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
9.77%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
7.32%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
15.65%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
11.44%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 3)
  • Yes Debt to equity is below 0.5 (0.05)
  • No Return on equity is 15% or more (11.4%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.5%
Low 1081.0000 · High 1139.9000
1W return
1.3%
Low 1065.4500 · High 1139.9000
1M return
9.8%
Low 986.1000 · High 1181.9000
52W return
16.0%
Low 697.4000 · High 1181.9000
Lifetime High ₹1154.7500 (Sept. 7, 2026)
Lifetime Low ₹205.0500 (June 20, 2022)

Full price history and technicals →

EMA & SMA

Bullish4
Bearish2
5D
1096.5
10D
1098.4
20D
1085.0
50D
1018.0
100D
947.9
200D
853.1

Delivery and volume

Day avg. delivery
50.1%
Week avg. delivery
44.1%
Month avg. delivery
34.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1104.07
Pivot
First resistance1127.13
Second resistance1162.97
Third resistance1186.03
First support1068.23
Second support1045.17
Third support1009.33
Day RSI55.3
Day MFI50.6
Day MACD26.02
Day MACD signal35.98

Beta

1M-0.27
3M0.09
1Y0.72
3Y0.95

Price change analysis

↑ 9.8%
Over 1 Month
LowHigh
986.101181.90
↑ 26.7%
Over 3 Months
LowHigh
808.051181.90
↑ 42.2%
Over 6 Months
LowHigh
746.551181.90
↑ 16.0%
Over 1 Year
LowHigh
697.401181.90
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 34.5 (own history: 18.3–35.9)
Sell Zone
Revenue (June 30, 2026)
₹248 Cr
Net profit (June 30, 2026)
₹18 Cr
Basic EPS (June 30, 2026)
₹8.4600

Ranks #78 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter63.31%
  • Mutual funds5.76%
  • FII/FPI2.04%
  • Other DII4.08%
  • Public24.81%

Largest holders

NameCategoryShares %Shares
AKW WBL Family Private Trust (through its Trustees Ashok Vimla Trusteeship Services Private Limited)Promoter40.6100%8381340
Ashok Kumar WindlassPromoter21.3200%4400000
Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) FundPublic3.4200%705991
Mncl Capital Compounder Fund 2Public1.7000%350000
Bandhan Small Cap FundPublic1.4300%295367

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 63.31% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 0.99% to 2.04% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 6.41% to 5.76% in Jun 2026 qtr

4 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 0 insider trades, 6 SAST, 0 pledge events →

All insider and SAST disclosures →

DateClientDealActionQuantityPriceExchange
20 Feb 2025 AJAY KUMAR AGGARWAL Bulk Buy 144,995 787.4200 NSE
1 Mar 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 110,668 564.9400 NSE
1 Mar 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 110,668 565.9600 NSE
20 Sep 2021 KUBER INDIA FUND Bulk Sell 113,468 379.7300 NSE
16 Aug 2021 ICICI LTD TRADING A/C Bulk Sell 122,350 417.6200 NSE
16 Aug 2021 ALPHAGREP SECURITIES PRIVATE LIMITED Bulk Buy 116,009 425.2800 NSE
16 Aug 2021 ALPHAGREP SECURITIES PRIVATE LIMITED Bulk Sell 116,009 425.4200 NSE

All bulk and block deals →

Last 12 months ₹6.30 per share
Dividend yield 0.58%
Ex-dateSubjectPer share (₹)Record date
16 Jul 2026 Dividend - Rs 6.30 Per Share 6.3000 16 Jul 2026
21 Jul 2025 Dividend - Rs 5.80 Per Share 5.8000 21 Jul 2025
17 Sep 2024 Dividend - Rs 5.50 Per Share 5.5000 17 Sep 2024
5 Sep 2023 Annual General Meeting/Dividend - Rs 4 Per Share 4.0000 —
9 Sep 2022 Annual General Meeting/Dividend - Rs 3.50 Per Share 3.5000 —

Corporate Actions

Full history (7 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
24 Apr 2026BUYBACKBuy Back
17 Sep 2024OTHERAnnual General Meeting

All corporate actions →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
10 Aug 2026 Financial Results Yes
21 May 2026 Financial Results/Dividend Yes
17 Apr 2026 Buyback —
5 Feb 2026 Financial Results Yes
6 Nov 2025 Financial Results Yes

Corporate Announcements

All 417 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.05)
  • Comfortable interest coverage (17.0x)
  • Healthy liquidity (Current Ratio 1.95)
  • Strong revenue growth YoY (18.1%)

Weaknesses

  • Declining profit YoY (-0.1%)

Opportunities

Data unavailable.

Threats

Data unavailable.

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Windlas Biotech Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.